Europe - OSL:TRMED - NO0010597883 - Common Stock
The current stock price of TRMED.OL is 3.555 NOK. In the past month the price decreased by -5.92%. In the past year, price increased by 119.74%.
|  Symbol  |  Company Name  |  TA  |  FA  |  PE  |  Market Cap  | 
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 20.57 | 333.17B | ||
| AMG.DE | AMGEN INC | 13.32 | 135.36B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 15.8 | 131.38B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.63 | 129.96B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 24.98 | 93.95B | ||
| ARGX.BR | ARGENX SE | 65.58 | 43.44B | ||
| 1AE.DE | ARGENX SE | 93.37 | 43.00B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.44B | ||
| IDP.DE | BIOGEN INC | 9.46 | 19.21B | ||
| 0QF.DE | MODERNA INC | N/A | 9.16B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.99B | ||
| 1EXEL.MI | EXELIXIS INC | 17.06 | 8.26B | 
 Thor Medical ASA.engages in the producing and supplying alpha particle emitters for cancer therapy. The company is headquartered in Oslo, Oslo and currently employs 13 full-time employees. The company went IPO on 2014-07-07. The firm is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The firm is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The firm has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells
THOR MEDICAL ASA
Karenslyst alle 9C
Oslo OSLO NO
Employees: 9
Phone: 4797414000
Thor Medical ASA.engages in the producing and supplying alpha particle emitters for cancer therapy. The company is headquartered in Oslo, Oslo and currently employs 13 full-time employees. The company went IPO on 2014-07-07. The firm is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The firm is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The firm has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells
The current stock price of TRMED.OL is 3.555 NOK. The price increased by 6.44% in the last trading session.
TRMED.OL does not pay a dividend.
TRMED.OL has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
You can find the ownership structure of THOR MEDICAL ASA (TRMED.OL) on the Ownership tab.
ChartMill assigns a technical rating of 8 / 10 to TRMED.OL. When comparing the yearly performance of all stocks, TRMED.OL is one of the better performing stocks in the market, outperforming 96.78% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to TRMED.OL. While TRMED.OL seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months TRMED.OL reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS increased by 94.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.73% | ||
| ROE | -5.61% | ||
| Debt/Equity | 0.02 |